Adtraza subcutaneous injection 300 mg pen, manufactured by Leo Pharma, contains Tralokinumab (genetical recombination). This single-use pre-filled pen is indicated for moderate-to-severe atopic dermatitis in adults and adolescents aged 12 years and older who require systemic therapy. It is supplied as a 300mg/2mL kit with YJ code 4490409G2029.
Adtraza subcutaneous injection 300 mg pen
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →